Hong Kong-listed Chinese drugmaker: nuclear-medicine cancer therapies, critical-care and respiratory drugs, ophthalmology and heart-brain emergency medicines.
Hong Kong-listed Chinese drugmaker: nuclear-medicine cancer therapies, critical-care and respiratory drugs, ophthalmology and heart-brain emergency medicines.
Sells prescription drugs for emergency, critical-care, respiratory and eye conditions to hospitals, where older products face government bulk-purchase price cuts. Its growth push is nuclear medicine, radioactive cancer treatments, led by yttrium-90 microspheres already on sale, with in-house radioligand drugs in trials.
Moat: narrow (IP / patents, regulatory licence). Licensed specialty drugs and a scarce nuclear-medicine franchise; older products face procurement pricing pressure.
Headquarters: Wuhan, China · Employees: 12,614
Size Grand Pharmaceutical (0512.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.93B, the 415th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.29 on 18 Nov 2026.
Performance Over six months the shares fell 24.6%, against -5.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 7.3% over the last twelve months (peer median +11.1%); the operating margin is 13.3% (peer median 20.9%).
Valuation It trades at 9.4× forward earnings against a peer median of 22.8× (2nd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.1 points below its cost of capital (7.7% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$12.6B | HK$12.3B | HK$11.6B | HK$10.5B | HK$9.56B |
| Revenue growth | — | +5% | +11% | +10% | — |
| Gross profit | HK$6.55B | HK$6.78B | HK$6.74B | HK$6.52B | HK$5.95B |
| EBITDA | HK$2.32B | HK$2.13B | HK$2.55B | HK$3.06B | HK$2.91B |
| Net income | HK$1.13B | HK$1.24B | HK$2.47B | HK$1.88B | HK$2.08B |
| Free cash flow | HK$838M | HK$774M | HK$1.14B | HK$1.73B | HK$1.26B |
| Capital expenditure | HK$1.50B | HK$1.52B | HK$678M | HK$498M | HK$1.67B |
| Total debt | n/a | HK$4.72B | HK$4.44B | HK$3.40B | HK$4.48B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Grand Pharmaceutical 0512.HK | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% |
| China Medical System 0867.HK | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% |
| Hansoh Pharma 3692.HK | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0512.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | +1.7% | 6th lowest of 21 |
| 6-month return | -24.6% | -5.5% | 5th lowest of 21 |
| Distance from 52-week high | -51.5% | -28.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +7.3% | +11.1% | 7th lowest of 20 |
| Operating margin | 13.3% | 20.9% | 7th lowest of 20 |
| Forward P/E | 9.4× | 22.8× | 2nd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.2% | 5.3% | 5th least demanding of 13 |
| Growth delivered (Del g) | +14.1% | +12.5% | 7th highest of 13 |
| Hurdle (Req g minus delivered) | -12.8 pp | -6.3 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | -1.1 pp | +1.6 pp | 9th lowest of 20 |
| EV / EBITDA | 8.2× | 17.8× | 4th cheapest of 10 |
| Net debt / EBITDA | 1.6× | 1.1× | 5th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |